Публикации
В этом разделе представлены научные публикации о препарате
Фортека® (пролголимаб).
Фортека® (пролголимаб).
Публикации
Альманах клинических случаев
Сборник клинических случаев применения препарата Фортека® (Пролголимаб) у пациентов с нерезектабельной или метастатической меланомой в различных клинических ситуациях.
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
Prolgolimab is an IgG1 anti-PD-1 monoclonal antibody with the Fc-silencing ‘LALA’ mutation. The phase III DOMAJOR study assessed efficacy and safety of prolgolimab in combination with pemetrexed and platinum-based chemotherapy vs placebo in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Prolgolimab Triplet Shows Encouraging Efficacy/Safety in Advanced Cervical Cancer
Treatment with prolgolimab (BCD-100) in combination with chemotherapy and bevacizumab (Avastin) showed auspicious efficacy and an adequate safety profile in patients with recurrent or metastatic cervical cancer, according to findings from the phase 2 CAESURA clinical trial (NCT03912402).
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
Prolgolimab is an IgG1 anti–PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing ‘LALA’ mutation. We assessed the efficacy and safety of two dosing regimens of prolgolimab in patients with advanced melanoma in a multicenter open-label parallel-arm phase II trial (MIRACULUM). We present the final analysis after 1 year of follow-up and additional efficacy results from 2 years of follow-up.
Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma
MIRACULUM (NCT03269565) is a multicenter open-label parallel-arm phase II study investigating the antitumor activity of BCD-100, an IgG1 anti-PD-1 monoclonal antibody with Fc silencing “LALA” mutation, in patients with advanced melanoma. Interim analysis at 6-months is presented. Methods: Patients (pts) with unresectable or metastatic melanoma, without autoimmune disease, and no prior anti-PD-1 or anti-CTLA-4 therapy were...
еще